Bio-Path (BPTH) Competitors $0.22 +0.02 (+11.62%) As of 06/12/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. APM, ENSC, EVOK, ONCO, EYEN, DRMA, TTNP, TCRT, GLTO, and MTNBShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Aptorum Group (APM), Ensysce Biosciences (ENSC), Evoke Pharma (EVOK), Onconetix (ONCO), Eyenovia (EYEN), Dermata Therapeutics (DRMA), Titan Pharmaceuticals (TTNP), Alaunos Therapeutics (TCRT), Galecto (GLTO), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors Aptorum Group Ensysce Biosciences Evoke Pharma Onconetix Eyenovia Dermata Therapeutics Titan Pharmaceuticals Alaunos Therapeutics Galecto Matinas Biopharma Aptorum Group (NASDAQ:APM) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation. Does the media refer more to APM or BPTH? In the previous week, Bio-Path had 7 more articles in the media than Aptorum Group. MarketBeat recorded 8 mentions for Bio-Path and 1 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 1.89 beat Bio-Path's score of -0.23 indicating that Aptorum Group is being referred to more favorably in the media. Company Overall Sentiment Aptorum Group Very Positive Bio-Path Neutral Do analysts prefer APM or BPTH? Bio-Path has a consensus price target of $20.00, indicating a potential upside of 8,990.91%. Given Bio-Path's stronger consensus rating and higher probable upside, analysts clearly believe Bio-Path is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of APM or BPTH? 3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer APM or BPTH? Bio-Path received 241 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 52.32% of users gave Bio-Path an outperform vote. CompanyUnderperformOutperformAptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Bio-PathOutperform Votes28252.32% Underperform Votes25747.68% Which has better earnings & valuation, APM or BPTH? Aptorum Group has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K14.67-$2.83MN/AN/ABio-PathN/AN/A-$16.08MN/AN/A Which has more risk and volatility, APM or BPTH? Aptorum Group has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Is APM or BPTH more profitable? Aptorum Group's return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A Bio-Path N/A -2,842.40%-337.48% SummaryAptorum Group and Bio-Path tied by winning 7 of the 14 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.83M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / SalesN/A262.53411.84157.63Price / CashN/A65.8538.2534.64Price / Book0.316.597.064.69Net Income-$16.08M$143.75M$3.23B$248.14M7 Day Performance15.79%0.82%0.80%0.95%1 Month Performance22.29%12.09%9.71%5.74%1 Year Performance-89.00%4.46%32.12%14.73% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path2.132 of 5 stars$0.22+11.6%$20.00+8,990.9%-89.7%$1.83MN/A0.0010Short Interest ↑APMAptorum Group1.5216 of 5 stars$1.00+8.7%N/A-72.5%$5.35M$430K0.0030Positive NewsGap UpENSCEnsysce Biosciences0.3809 of 5 stars$2.22flatN/A-73.4%$5.26M$2.23M-0.0810Short Interest ↓EVOKEvoke Pharma0.6186 of 5 stars$3.52-0.8%N/A-54.9%$5.26M$11.59M-0.324Positive NewsONCOOnconetix0.711 of 5 stars$0.08+2.6%N/A-98.8%$5.16M$1.87M0.0012Earnings ReportStock SplitShort Interest ↓EYENEyenovia0.4782 of 5 stars$1.67flat$2.00+19.8%-94.9%$4.82M$67.06K-0.0340Positive NewsShort Interest ↑DRMADermata Therapeutics3.071 of 5 stars$0.70-2.8%$3.00+328.6%-75.6%$4.47MN/A-0.048Short Interest ↓TTNPTitan Pharmaceuticals1.19 of 5 stars$4.88+6.1%N/A-35.6%$4.46M$180K-1.0610Positive NewsShort Interest ↓TCRTAlaunos Therapeutics1.126 of 5 stars$2.70+9.8%N/A-69.4%$4.43M$11K0.0040GLTOGalecto2.5089 of 5 stars$3.20+4.2%$10.00+212.5%-74.7%$4.23MN/A-0.1740Short Interest ↑MTNBMatinas Biopharma0.8799 of 5 stars$0.82+0.6%N/AN/A$4.17M$1.10M-0.1730Short Interest ↓ Related Companies and Tools Related Companies APM Alternatives ENSC Alternatives EVOK Alternatives ONCO Alternatives EYEN Alternatives DRMA Alternatives TTNP Alternatives TCRT Alternatives GLTO Alternatives MTNB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
